Syndecan-1 Depletion Has a Differential Impact on Hyaluronic Acid Metabolism and Tumor Cell Behavior in Luminal and Triple-Negative Breast Cancer Cells

Int J Mol Sci. 2021 May 30;22(11):5874. doi: 10.3390/ijms22115874.

Abstract

Glycosaminoglycans (GAGs) and proteoglycans (PGs) are major components of the glycocalyx. The secreted GAG and CD44 ligand hyaluronic acid (HA), and the cell surface PG syndecan-1 (Sdc-1) modulate the expression and activity of cytokines, chemokines, growth factors, and adhesion molecules, acting as critical regulators of tumor cell behavior. Here, we studied the effect of Sdc-1 siRNA depletion and HA treatment on hallmark processes of cancer in breast cancer cell lines of different levels of aggressiveness. We analyzed HA synthesis, and parameters relevant to tumor progression, including the stem cell phenotype, Wnt signaling constituents, cell cycle progression and apoptosis, and angiogenic markers in luminal MCF-7 and triple-negative MDA-MB-231 cells. Sdc-1 knockdown enhanced HAS-2 synthesis and HA binding in MCF-7, but not in MDA-MB-231 cells. Sdc-1-depleted MDA-MB-231 cells showed a reduced CD24-/CD44+ population. Furthermore, Sdc-1 depletion was associated with survival signals in both cell lines, affecting cell cycle progression and apoptosis evasion. These changes were linked to the altered expression of KLF4, MSI2, and miR-10b and differential changes in Erk, Akt, and PTEN signaling. We conclude that Sdc-1 knockdown differentially affects HA metabolism in luminal and triple-negative breast cancer model cell lines and impacts the stem phenotype, cell survival, and angiogenic factors.

Keywords: angiogenesis; apoptosis; breast cancer; hyaluronic acid; stem cells; syndecan-1.

MeSH terms

  • Apoptosis / drug effects
  • Apoptosis / genetics
  • CD24 Antigen / genetics
  • CD24 Antigen / metabolism
  • Cell Cycle / drug effects
  • Cell Cycle / genetics
  • Cell Line, Tumor
  • Databases, Factual
  • Female
  • Gene Expression Regulation, Neoplastic*
  • Glycocalyx / chemistry
  • Glycocalyx / drug effects
  • Glycocalyx / metabolism*
  • Humans
  • Hyaluronan Receptors / genetics
  • Hyaluronan Receptors / metabolism
  • Hyaluronan Synthases / genetics
  • Hyaluronan Synthases / metabolism
  • Hyaluronic Acid / metabolism*
  • Hyaluronic Acid / pharmacology
  • Kruppel-Like Factor 4
  • Kruppel-Like Transcription Factors / genetics
  • Kruppel-Like Transcription Factors / metabolism
  • MCF-7 Cells
  • MicroRNAs / genetics
  • MicroRNAs / metabolism
  • Mitogen-Activated Protein Kinase 1 / genetics
  • Mitogen-Activated Protein Kinase 1 / metabolism
  • Mitogen-Activated Protein Kinase 3 / genetics
  • Mitogen-Activated Protein Kinase 3 / metabolism
  • PTEN Phosphohydrolase / genetics
  • PTEN Phosphohydrolase / metabolism
  • Protein Binding
  • Proto-Oncogene Proteins c-akt / genetics
  • Proto-Oncogene Proteins c-akt / metabolism
  • RNA, Small Interfering / genetics
  • RNA, Small Interfering / metabolism
  • RNA-Binding Proteins / genetics
  • RNA-Binding Proteins / metabolism
  • Survival Analysis
  • Syndecan-1 / antagonists & inhibitors
  • Syndecan-1 / genetics*
  • Syndecan-1 / metabolism
  • Triple Negative Breast Neoplasms / genetics*
  • Triple Negative Breast Neoplasms / metabolism
  • Triple Negative Breast Neoplasms / mortality
  • Triple Negative Breast Neoplasms / pathology
  • Wnt Signaling Pathway / genetics*

Substances

  • CD24 Antigen
  • CD44 protein, human
  • Hyaluronan Receptors
  • KLF4 protein, human
  • Kruppel-Like Factor 4
  • Kruppel-Like Transcription Factors
  • MIRN10 microRNA, human
  • MSI2 protein, human
  • MicroRNAs
  • RNA, Small Interfering
  • RNA-Binding Proteins
  • SDC1 protein, human
  • Syndecan-1
  • Hyaluronic Acid
  • HAS2 protein, human
  • Hyaluronan Synthases
  • Proto-Oncogene Proteins c-akt
  • MAPK1 protein, human
  • MAPK3 protein, human
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • PTEN Phosphohydrolase
  • PTEN protein, human